Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

The researchers tested whether a ctDNA-guided strategy could lower the need for adjuvant chemotherapy without increasing the risk of recurrence. Recurrence-free survival at 2 years was the main efficacy end objective. Adjuvant chemotherapy usage was a significant secondary end goal.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form